Swedish Orphan Biovit Ord


By |


Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hemophilia, immunology, and hereditary conditions. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement development programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi recently acquired rights to pipeline therapy emapalumab and has a pending deal to acquire U.S. rights to Astra's Synagis.

Contact Information

Website: www.sobi.com
Email: info@sobi.com
Main Phone: +46 86972000
Address: Tomtebodavagen 23 A
Address 2: Solna
City / Town: Stockholm
Country: SWE
Postal Code: SE-112 76

Issuer Information

Exchange: OTO
Employees: 842
$ 22.90 $ 0. (0.00%)
Last Price 22.90 Change $ 0. Change % 0.00 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close 22.90
Last Trade Volume 0 52 Wk Hi 31.25 52 Wk Low 16.36
Market Cap 6.2 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 269,656,920.00 EPS (TTM) N/A PE Ratio N/A Exchange OTCPK